Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Eight Things To Know From Novartis' Third Quarter Call

Oct 18 2018

• By Jessica Merrill

business documents accounting with calculator and magnifying glass. concept for financial

Related Content

Novartis Aims Canakinumab At Targeted CV Patients

Nov 13 2017

Novartis’s Luxturna Deal Expands Gene Therapy Ambitions

Jan 25 2018

Novartis Goes Big On Gene Therapy With $8.7bn AveXis Acquisition

Apr 09 2018

Three Strikes For Generic Advair With An FDA CRL For Sandoz

Feb 08 2018

CDK4/6 Inhibitor Market Snapshot: New Drugs Jockey For A Piece Of The Multi-Billion Dollar Pie

Jun 19 2018

Cosentyx Carries Novartis Sales But Kymriah Manufacturing Gives Cause For Concern

Jul 18 2018

Related Companies

Novartis AG

Endocyte, Inc.

Johnson & Johnson

Amgen, Inc.

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Express Scripts Holding Company

Pfizer Inc.

Biogen, Inc.

AveXis, Inc.

Spark Therapeutics, Inc.

GSK plc

Viatris Inc.

Additional Topics

Sales & Earnings Launches Business Strategies Commercial Complete Response Letters BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window